Sujith Kalmadi

902 total citations
26 papers, 427 citations indexed

About

Sujith Kalmadi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sujith Kalmadi has authored 26 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Sujith Kalmadi's work include Cancer Treatment and Pharmacology (5 papers), Cancer Genomics and Diagnostics (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Sujith Kalmadi is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer Genomics and Diagnostics (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Sujith Kalmadi collaborates with scholars based in United States, Spain and Italy. Sujith Kalmadi's co-authors include Alejandro C. Arroliga, Robin K. Avery, Steven M. Gordon, Steven P. LaRosa, David L. Longworth, Tao Jin, Ramón V. Tiu, Matt Kalaycio, Christopher J. Lowe and David J. Adelstein and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Sujith Kalmadi

24 papers receiving 413 citations

Peers

Countries citing papers authored by Sujith Kalmadi

Since Specialization

Citations

This map shows the geographic impact of Sujith Kalmadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sujith Kalmadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sujith Kalmadi more than expected).

Fields of papers citing papers by Sujith Kalmadi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sujith Kalmadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sujith Kalmadi. The network helps show where Sujith Kalmadi may publish in the future.

Co-authorship network of co-authors of Sujith Kalmadi

This figure shows the co-authorship network connecting the top 25 collaborators of Sujith Kalmadi. A scholar is included among the top collaborators of Sujith Kalmadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sujith Kalmadi. Sujith Kalmadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. 2025 ·Journal of Clinical Oncology ·(unknown), Vasily N. Aushev, Joe Ensor, Stephanie Sanchez, (unknown), Timothy Lewis Cannon, Lyudmyla Berim, Trevor Feinstein, Axel Grothey, (unknown), Sujith Kalmadi, Ahmed Zakari, (unknown), Donald Gravenor, Minetta C. Liu, Adham Jurdi, Alexey Aleshin, (unknown), Saima Sharif, Scott Kopetz	2
2	Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study. 2024 ·Journal of Clinical Oncology ·Pashtoon Murtaza Kasi, Vasily N. Aushev, Joe Ensor, (unknown), (unknown), Timothy Lewis Cannon, Lyudmyla Berim, Trevor Feinstein, Axel Grothey, (unknown), Sujith Kalmadi, Ahmed Zakari, Farshid Dayyani, Donald Gravenor, (unknown), Saima Sharif, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Scott Kopetz	37
3	Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region 2023 ·Frontiers in Oncology ·Milan J. Anadkat, Mario E. Lacouture, Adam Friedman, Zachary D. Horne, Jae U. Jung, Benjamin H. Kaffenberger, Sujith Kalmadi, Liza G. Ovington, Rupesh Kotecha, (unknown), Federica Grosso	9
4	Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials 2022 ·Cancer Research ·Claudine Isaacs, Reshma Mahtani, Filipa Lynce, Bethany Sleckman, Aurelio Castrellon, Sujith Kalmadi, Kathy Puyana Theall, (unknown), Eustratios Bananis, Hope S. Rugo	1
5	Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials 2021 ·Cancer Medicine ·Renata Ferrarotto, Ian C. Anderson, Balazs Medgyasszay, M.R. García-Campelo, William J. Edenfield, Trevor Feinstein, Jennifer M. Johnson, Sujith Kalmadi, Philip E. Lammers, (unknown), Yili Pritchett, Shannon R. Morris, Rajesh Malik, Tibor Csőszi	37
6	Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens 2021 ·Cancer Research ·Beverly Moy, Mafalda Oliveira, Cristina Saura, William J. Gradishar, Sung‐Bae Kim, Adam Brufsky, Sara A. Hurvitz, Larisa Ryvo, Daniele Fagnani, Nancy Chan, Sujith Kalmadi, Paula Silverman, Suzette Delaloge, Richard Bryce, Kiana Keyvanjah, Judith D. Bebchuk, Bo Zhang, Nina Oestreicher, Ron Bose	0
7	Predictors of clinical outcomes of resected ampullary adenocarcinoma: A single-institution experience 2011 ·European Journal of Surgical Oncology ·Aleksandr Lazaryan, Sujith Kalmadi, Khaldoun Almhanna, Robert Pelley, (unknown)	22
8	Clinical Utility of Temozolomide in the Treatment of Malignant Paraganglioma: A Preliminary Report 2009 ·Hormone and Metabolic Research ·E L Bravo, Sujith Kalmadi, Inderbir S. Gill	17
9	Evolving perspectives of the role of novel agents in androgen-independent prostate cancer 2008 ·Indian Journal of Urology ·Sujith Kalmadi, Derek Raghavan	1
10	Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810) 2007 ·Lung Cancer ·Sujith Kalmadi, Cathryn Rankin, Michael Kraut, Andrew Jacobs, Daniel P. Petrylak, David J. Adelstein, Mary Louise Keohan, Robert N. Taub, Ernest C. Borden	50
11	Lenalidomide: The emerging role of a novel targeting agent inmalignancies 2007 ·Drugs of today ·Sujith Kalmadi, Rachid Baz, Anuj Mahindra	4
12	Treatment Approaches for Hepatocellular Carcinoma 2007 ·SHILAP Revista de lepidopterología ·Khaldoun Almhanna, Richard D. Kim, Sujith Kalmadi	2
13	The Emerging Role of Arsenic Trioxide as an Immunomodulatory Agent in the Management of Multiple Myeloma 2006 ·Acta Haematologica ·Sujith Kalmadi, Mohamad A. Hussein	16
14	Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage 2006 ·Cancer ·Sujith Kalmadi, Ramón V. Tiu, Christopher J. Lowe, Tao Jin, Matt Kalaycio	44
15	Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors 2006 ·Investigational New Drugs ·Sujith Kalmadi, Timothy M. E. Davis, Afshin Dowlati, Stephen J. O’Keefe, (unknown), Robert Pelley, Ernest C. Borden, Robert Dreicer, Ronald M. Bukowski, Tarek Mekhail	17
16	Phase II Trial of Weekly Docetaxel and Gemcitabine as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer 2006 ·Medical Oncology ·Sujith Kalmadi, (unknown), (unknown), David M. Peereboom, David J. Adelstein, Tarek Mekhail	10
17	Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer 2006 ·Journal of Clinical Oncology ·(unknown), Sujith Kalmadi, (unknown), David M. Peereboom, David J. Adelstein, Ronald M. Bukowski, Tarek Mekhail	2
18	Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors 2006 ·Journal of Clinical Oncology ·Sujith Kalmadi, (unknown), Afshin Dowlati, Stephen J. O’Keefe, (unknown), Robert Pelley, Ernest C. Borden, (unknown), Ronald M. Bukowski, Tarek Mekhail	1
19	Weekly docetaxel-gemcitabine as first-line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study 2004 ·Journal of Clinical Oncology ·Sujith Kalmadi, Tarek Mekhail, David J. Adelstein, Caterina Giannini, David M. Peereboom, Thomas Olencki, (unknown), Ronald Bukowski	1
20	Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued? 1999 ·Clinical Infectious Diseases ·Steven M. Gordon, Steven P. LaRosa, Sujith Kalmadi, Alejandro C. Arroliga, Robin K. Avery, (unknown), David L. Longworth	138

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact